2023
Naltrexone/bupropion for binge‐eating disorder: A randomized, double‐blind, placebo‐controlled trial
Grilo C, Lydecker J, Jastreboff A, Pittman B, McKee S. Naltrexone/bupropion for binge‐eating disorder: A randomized, double‐blind, placebo‐controlled trial. Obesity 2023, 31: 2762-2773. PMID: 37751990, PMCID: PMC10600891, DOI: 10.1002/oby.23898.Peer-Reviewed Original ResearchConceptsNaltrexone/bupropionBinge-eating disorderObesity statusLogistic regressionWeight lossPlacebo-controlled trialWeight loss outcomesPrevalent psychiatric disordersEvidence-based treatmentsPost-treatment assessmentBinge-eating frequencyGreater percentage weight lossMedication outcomesRemission ratePharmacological optionsPlaceboBupropionPsychiatric disordersPercentage weight lossMixed modelsDisordersObesityPatientsSignificant reductionWeight reduction
2016
Sex Differences in Smoking Cessation Pharmacotherapy Comparative Efficacy: A Network Meta-analysis
Smith PH, Weinberger AH, Zhang J, Emme E, Mazure CM, McKee SA. Sex Differences in Smoking Cessation Pharmacotherapy Comparative Efficacy: A Network Meta-analysis. Nicotine & Tobacco Research 2016, 19: 273-281. PMID: 27613893, PMCID: PMC5939704, DOI: 10.1093/ntr/ntw144.Peer-Reviewed Original ResearchConceptsTransdermal nicotineSmoking cessationBupropion SRComparative efficacyFirst option treatmentSustained release bupropionPlacebo-controlled trialSex differencesCigarette smoking cessationNetwork Meta-AnalysisRelease bupropionCessation pharmacotherapyOption treatmentGeneral community sampleCigarette smokersQuit ratesVarenicline's efficacyPharmacological interventionsVareniclineBupropionNicotine addictionMeta-AnalysisPlaceboSimilar outcomesSignificant sex differences
2007
Subjective reactivity to the first cigarette of the day as a predictor of smoking relapse: A preliminary study
Toll BA, Schepis TS, O’Malley S, McKee SA, Krishnan-Sarin S. Subjective reactivity to the first cigarette of the day as a predictor of smoking relapse: A preliminary study. Drug And Alcohol Dependence 2007, 89: 302-305. PMID: 17320313, PMCID: PMC2475673, DOI: 10.1016/j.drugalcdep.2007.01.011.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAffectAgedAntidepressive Agents, Second-GenerationBehavior TherapyBupropionCircadian RhythmDelayed-Action PreparationsFemaleHumansMaleMiddle AgedMotivationNicotineOutcome Assessment, Health CarePrognosisSecondary PreventionSmokingSmoking CessationSubstance Withdrawal SyndromeSurveys and QuestionnairesTobacco Use DisorderConceptsFirst cigaretteSmoking relapseEnd of treatmentCessation treatment outcomeInitial cigaretteWithdrawal symptomsClinical trialsQuit dayTreatment outcomesNovel predictorRelapseCigarettesPreliminary studyTime pointsGreater decreaseCravingSubjective responsesSubjective reactivityDaysFuture studiesSignificant changesWithdrawalPredictorsResponseBupropion